FindTrial
Sign In

RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine

RElapse in previously irradiated Prostate bed : a phase I/II study of stereotactic Ablative reIRradiation potentiated by Metformine - REPAIR-GETUG P16

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2020-001685-11-FR
Enrollment
44
Registered
2020-05-11
Start date
2020-06-26
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RElapse in previously irradiated Prostate bed

Interventions

Trade Name: METFORMINE Product Name: METFORMINE Product Code: 397 059-0 Pharmaceutical Form: Coated tablet Product Name: SBRT (Stereotactic Body Radiation Therapy) Pharmaceutical Form:

Sponsors

INSTITUT DE CANCEROLOGIE DE L'OUEST
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 14 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 30

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

France

Contacts

Public ContactDRCI

INSTITUT DE CANCEROLOGIE DE L'OUEST

drci@ico.unicancer.fr33240 67 99 08

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026